Baxter International last week settled Justice Department allegations regarding flaws with two of its medical infusion pumps, saying it would halt manufacture and distribution of the pumps until the problems are fixed. "The agreement we've reached with FDA provides a clear path to resolving Colleague and Syndeo issues, so that we may continue to serve patients and medical professionals by delivering the quality, reliability and innovation they expect from Baxter," Baxter's chairman and CEO said. An analyst said, "This is a very serious regulatory step that allows FDA significant power to oversee and shape the rebuilding of Baxter's quality systems in the coming years."

Related Summaries